{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T19:14:47Z","timestamp":1795029287426,"version":"4.10.2"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:00:00Z","timestamp":1625184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:00:00Z","timestamp":1625184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Parkinson\u2019s disease (PD) is a progressive neurodegenerative disease with no cure and few treatment options. Its incidence is increasing due to aging populations, longer disease duration and potentially as a COVID-19 sequela. Photobiomodulation (PBM) has been successfully used in animal models to reduce the signs of PD and to protect dopaminergic neurons.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the effectiveness of PBM to mitigate clinical signs of PD in a prospective proof-of-concept study, using a combination of transcranial and remote treatment, in order to inform on best practice for a larger randomized placebo-controlled trial (RCT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Twelve participants with idiopathic PD were recruited. Six were randomly chosen to begin 12\u2009weeks of transcranial, intranasal, neck and abdominal PBM. The remaining 6 were waitlisted for 14\u2009weeks before commencing the same\u00a0treatment. After the 12-week treatment period, all participants were supplied with PBM devices to continue home treatment. Participants were assessed for mobility, fine motor skills, balance and cognition before treatment began, after 4\u2009weeks of treatment, after 12\u2009weeks of treatment and the end of the home treatment period. A Wilcoxon Signed Ranks test was used to assess treatment effectiveness at a significance level of 5%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Measures of mobility, cognition, dynamic balance and fine motor skill were significantly improved (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05) with PBM treatment for 12\u2009weeks and up to one year. Many individual improvements were above the minimal clinically important difference, the threshold judged to be meaningful for participants. Individual improvements varied but many continued for up to one year with sustained home treatment. There was a demonstrable Hawthorne Effect that was below the treatment effect. No side effects of the treatment were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PBM was shown to be a safe and potentially effective treatment for a range of clinical signs and symptoms of PD. Improvements were maintained for as long as treatment continued, for up to one year in a neurodegenerative disease where decline is typically expected. Home treatment of PD by the person themselves or with the help of a carer might be an effective therapy option. The results of this study indicate that a large RCT is warranted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      Australian New Zealand Clinical Trials Registry, registration number:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=373999&amp;isReview=true\">ACTRN12618000038291p<\/jats:ext-link>\n                      , registered on 12\/01\/2018.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-021-02248-y","type":"journal-article","created":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:02:34Z","timestamp":1625184154000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":110,"title":["Improvements in clinical signs of Parkinson\u2019s disease using photobiomodulation: a prospective proof-of-concept study"],"prefix":"10.1186","volume":"21","author":[{"given":"Ann","family":"Liebert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Bicknell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E-Liisa","family":"Laakso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Heller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parastoo","family":"Jalilitabaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Tilley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mitrofanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hosen","family":"Kiat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,2]]},"reference":[{"issue":"11","key":"2248_CR1","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S1474-4422(18)30355-7","volume":"17","author":"WA Rocca","year":"2018","unstructured":"Rocca WA. The burden of Parkinson's disease: a worldwide perspective. Lancet Neurol. 2018;17(11):928\u20139. https:\/\/doi.org\/10.1016\/S1474-4422(18)30355-7.","journal-title":"Lancet Neurol."},{"key":"2248_CR2","first-page":"1","volume":"Preprint","author":"LC Beauchamp","year":"2020","unstructured":"Beauchamp LC, Finkelstein DI, Bush AI, Evans AH, Barnham KJ. Parkinsonism as a third wave of the COVID-19 pandemic? J Parkinson's Dis. 2020;Preprint:1\u201311.","journal-title":"J Parkinson's Dis"},{"issue":"3","key":"2248_CR3","doi-asserted-by":"publisher","first-page":"899","DOI":"10.3233\/JPD-202073","volume":"10","author":"DB Victorino","year":"2020","unstructured":"Victorino DB, Guimar\u00e3es-Marques M, Nejm M, Scorza FA, Scorza CA. COVID-19 and Parkinson\u2019s disease: are we dealing with short-term impacts or something worse? J Parkinsons Dis. 2020;10(3):899\u2013902. https:\/\/doi.org\/10.3233\/JPD-202073.","journal-title":"J Parkinsons Dis"},{"key":"2248_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.pneurobio.2018.09.003","volume":"177","author":"A Gr\u00fcnewald","year":"2019","unstructured":"Gr\u00fcnewald A, Kumar KR, Sue CM. New insights into the complex role of mitochondria in Parkinson\u2019s disease. Prog Neurobiol. 2019;177:73\u201393. https:\/\/doi.org\/10.1016\/j.pneurobio.2018.09.003.","journal-title":"Prog Neurobiol"},{"issue":"8","key":"2248_CR5","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/mds.27372","volume":"33","author":"SH Fox","year":"2018","unstructured":"Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K, et al. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson's disease. Mov Disord. 2018;33(8):1248\u201366. https:\/\/doi.org\/10.1002\/mds.27372.","journal-title":"Mov Disord"},{"issue":"s1","key":"2248_CR6","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.3233\/JPD-181477","volume":"8","author":"F Scheperjans","year":"2018","unstructured":"Scheperjans F, Derkinderen P, Borghammer P. The gut and Parkinson's disease: hype or Hope? J Parkinsons Dis. 2018;8(s1):S31\u2013S9. https:\/\/doi.org\/10.3233\/JPD-181477.","journal-title":"J Parkinsons Dis"},{"key":"2248_CR7","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.parkreldis.2019.08.010","volume":"66","author":"M Lubomski","year":"2019","unstructured":"Lubomski M, Davis RL, Sue CM. The gut microbiota: a novel therapeutic target in Parkinson's disease? Parkinsonism Relat Disord. 2019;66:265\u20136. https:\/\/doi.org\/10.1016\/j.parkreldis.2019.08.010.","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"2248_CR8","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/php.12864","volume":"94","author":"MR Hamblin","year":"2018","unstructured":"Hamblin MR. Mechanisms and mitochondrial redox signaling in Photobiomodulation. Photochem Photobiol. 2018;94(2):199\u2013212. https:\/\/doi.org\/10.1111\/php.12864.","journal-title":"Photochem Photobiol"},{"key":"2248_CR9","doi-asserted-by":"publisher","first-page":"111916","DOI":"10.1016\/j.jphotobiol.2020.111916","volume":"208","author":"P Benson","year":"2020","unstructured":"Benson P, Kim JY, Riveros C, Camp A, Johnstone DM. Elucidating the time course of the transcriptomic response to photobiomodulation through gene co-expression analysis. J Photochem Photobiol B Biol. 2020;208:111916. https:\/\/doi.org\/10.1016\/j.jphotobiol.2020.111916.","journal-title":"J Photochem Photobiol B Biol"},{"issue":"1","key":"2248_CR10","doi-asserted-by":"publisher","first-page":"10581","DOI":"10.1038\/srep10581","volume":"5","author":"I Khan","year":"2015","unstructured":"Khan I, Tang E, Arany P. Molecular pathway of near-infrared laser phototoxicity involves ATF-4 orchestrated ER stress. Sci Rep. 2015;5(1):10581. https:\/\/doi.org\/10.1038\/srep10581.","journal-title":"Sci Rep"},{"issue":"10","key":"2248_CR11","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1007\/s00221-017-5048-7","volume":"235","author":"C Moro","year":"2017","unstructured":"Moro C, Torres N, Arvanitakis K, Cullen K, Chabrol C, Agay D, et al. No evidence for toxicity after long-term photobiomodulation in normal non-human primates. Exp Brain Res. 2017;235(10):3081\u201392. https:\/\/doi.org\/10.1007\/s00221-017-5048-7.","journal-title":"Exp Brain Res"},{"issue":"10","key":"2248_CR12","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1089\/photob.2019.4678","volume":"37","author":"P Cassano","year":"2019","unstructured":"Cassano P, Caldieraro MA, Norton R, Mischoulon D, Trinh N-H, Nyer M, et al. Reported side effects, weight and blood pressure, after repeated sessions of transcranial Photobiomodulation. Photobiomodul Photomed Laser Surg. 2019;37(10):651\u20136. https:\/\/doi.org\/10.1089\/photob.2019.4678.","journal-title":"Photobiomodul Photomed Laser Surg."},{"issue":"6","key":"2248_CR13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1042\/BIO03806024","volume":"38","author":"MR Hamblin","year":"2016","unstructured":"Hamblin MR. Photobiomodulation and the brain\u2013has the light dawned? Biochemist. 2016;38(6):24\u20138. https:\/\/doi.org\/10.1042\/BIO03806024.","journal-title":"Biochemist"},{"issue":"3","key":"2248_CR14","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3934\/biophy.2017.3.337","volume":"4","author":"MR Hamblin","year":"2017","unstructured":"Hamblin MR. Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophys. 2017;4(3):337\u201361. https:\/\/doi.org\/10.3934\/biophy.2017.3.337.","journal-title":"AIMS Biophys"},{"issue":"3","key":"2248_CR15","doi-asserted-by":"publisher","first-page":"349","DOI":"10.4103\/1673-5374.153673","volume":"10","author":"DM Johnstone","year":"2015","unstructured":"Johnstone DM, Mitrofanis J, Stone J. Targeting the body to protect the brain: inducing neuroprotection with remotely-applied near infrared light. Neural Regen Res. 2015;10(3):349\u201351. https:\/\/doi.org\/10.4103\/1673-5374.153673.","journal-title":"Neural Regen Res"},{"issue":"3","key":"2248_CR16","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.mehy.2013.12.009","volume":"82","author":"A Liebert","year":"2014","unstructured":"Liebert A, Bicknell B, Adams R. Protein conformational modulation by photons: a mechanism for laser treatment effects. Med Hypotheses. 2014;82(3):275\u201381. https:\/\/doi.org\/10.1016\/j.mehy.2013.12.009.","journal-title":"Med Hypotheses"},{"issue":"11","key":"2248_CR17","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1089\/pho.2015.3988","volume":"34","author":"A Blatt","year":"2016","unstructured":"Blatt A, Elbaz-Greener GA, Tuby H, Maltz L, Siman-Tov Y, Ben-Aharon G, et al. Low-level laser therapy to the bone marrow reduces scarring and improves heart function post-acute myocardial infarction in the pig. Photomed Laser Surg. 2016;34(11):516\u201324. https:\/\/doi.org\/10.1089\/pho.2015.3988.","journal-title":"Photomed Laser Surg"},{"issue":"1","key":"2248_CR18","doi-asserted-by":"publisher","first-page":"015003","DOI":"10.1117\/1.NPh.3.1.015003","volume":"3","author":"MV Pires de Sousa","year":"2016","unstructured":"Pires de Sousa MV, Ferraresi C, Kawakubo M, Kaippert B, Yoshimura EM, Hamblin MR. Transcranial low-level laser therapy (810 nm) temporarily inhibits peripheral nociception: photoneuromodulation of glutamate receptors, prostatic acid phophatase, and adenosine triphosphate. Neurophotonics. 2016;3(1):015003.","journal-title":"Neurophotonics"},{"issue":"4","key":"2248_CR19","doi-asserted-by":"publisher","first-page":"610","DOI":"10.3390\/biom10040610","volume":"10","author":"F Salehpour","year":"2020","unstructured":"Salehpour F, Hamblin MR. Photobiomodulation for Parkinson\u2019s disease in animal models: a systematic review. Biomolecules. 2020;10(4):610. https:\/\/doi.org\/10.3390\/biom10040610.","journal-title":"Biomolecules."},{"issue":"1","key":"2248_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/cne.22207","volume":"518","author":"V Shaw","year":"2010","unstructured":"Shaw V, Ashkan K, Benabid A, Stone J, Baker G, Mitrofanis J. Neuroprotection of midbrain dopaminergic cell in MPTP-treated mice after near-infrared light treatment. J Comp Neurol. 2010;518(1):25\u201340. https:\/\/doi.org\/10.1002\/cne.22207.","journal-title":"J Comp Neurol"},{"issue":"1","key":"2248_CR21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/alzrt232","volume":"6","author":"S Purushothuman","year":"2014","unstructured":"Purushothuman S, Johnstone D, Nandasena C, Mitrofanis J, Stone J. Photobiomodulation with near infrared light mitigates Alzheimer's disease-related pathology in cerebral cortex - evidence from two transgenic mouse models. Alzheimers Res Ther. 2014;6(1):2. https:\/\/doi.org\/10.1186\/alzrt232.","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"2248_CR22","doi-asserted-by":"publisher","first-page":"574","DOI":"10.4103\/1673-5374.205092","volume":"12","author":"J Mitrofanis","year":"2017","unstructured":"Mitrofanis J. Why and how does light therapy offer neuroprotection in Parkinson's disease? Neural Regen Res. 2017;12(4):574\u20135. https:\/\/doi.org\/10.4103\/1673-5374.205092.","journal-title":"Neural Regen Res"},{"key":"2248_CR23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.arr.2017.05.005","volume":"37","author":"B Kim","year":"2017","unstructured":"Kim B, Brandli A, Mitrofanis J, Stone J, Purushothuman S, Johnstone DM. Remote tissue conditioning - an emerging approach for inducing body-wide protection against diseases of ageing. Ageing Res Rev. 2017;37:69\u201378. https:\/\/doi.org\/10.1016\/j.arr.2017.05.005.","journal-title":"Ageing Res Rev"},{"key":"2248_CR24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.neuroscience.2018.12.050","volume":"400","author":"V Ganeshan","year":"2019","unstructured":"Ganeshan V, Skladnev NV, Kim JY, Mitrofanis J, Stone J, Johnstone DM. Pre-conditioning with remote photobiomodulation modulates the brain transcriptome and protects against MPTP insult in mice. Neuroscience. 2019;400:85.","journal-title":"Neuroscience"},{"issue":"12","key":"2248_CR25","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.4103\/1673-5374.262573","volume":"14","author":"LC Gordon","year":"2019","unstructured":"Gordon LC, Johnstone DM. Remote photobiomodulation: an emerging strategy for neuroprotection. Neural Regen Res. 2019;14(12):2086\u20137. https:\/\/doi.org\/10.4103\/1673-5374.262573.","journal-title":"Neural Regen Res"},{"key":"2248_CR26","volume-title":"The helmet experiment in Parkinson's disease: an observation of the mechanism of neuroprotection by near infra-red light","author":"J Stone","year":"2013","unstructured":"Stone J, Johnstone D, Mitrofanis J. The helmet experiment in Parkinson's disease: an observation of the mechanism of neuroprotection by near infra-red light. Gold Coast: 9th WALT Congress; 2013."},{"issue":"3","key":"2248_CR27","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.brs.2019.02.009","volume":"12","author":"L Santos","year":"2019","unstructured":"Santos L, del Olmo-Aguado S, Valenzuela PL, Winge K, Iglesias-Soler E, Arg\u00fcelles-Luis J, et al. Photobiomodulation in Parkinson's disease: a randomized controlled trial. Brain Stimul. 2019;12(3):810\u20132. https:\/\/doi.org\/10.1016\/j.brs.2019.02.009.","journal-title":"Brain Stimul"},{"issue":"10","key":"2248_CR28","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1089\/photob.2019.4663","volume":"37","author":"CL Hamilton","year":"2019","unstructured":"Hamilton CL, El Khoury H, Hamilton D, Nicklason F, Mitrofanis J. \u201cBuckets\u201d: early observations on the use of red and infrared light helmets in Parkinson's disease patients. Photobiomodul Photomed Laser Surg. 2019;37(10):615\u201322. https:\/\/doi.org\/10.1089\/photob.2019.4663.","journal-title":"Photobiomodul Photomed Laser Surg"},{"issue":"10","key":"2248_CR29","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1089\/photob.2019.4685","volume":"37","author":"MH Berman","year":"2019","unstructured":"Berman MH, Nichols TW. Treatment of neurodegeneration: integrating Photobiomodulation and neurofeedback in Alzheimer's dementia and Parkinson's: a review. Photobiomodul Photomed Laser Surg. 2019;37(10):623\u201334. https:\/\/doi.org\/10.1089\/photob.2019.4685.","journal-title":"Photobiomodul Photomed Laser Surg."},{"issue":"9","key":"2248_CR30","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1093\/ptj\/80.9.896","volume":"80","author":"A Shumway-Cook","year":"2000","unstructured":"Shumway-Cook A, Brauer S, Woollacott M. Predicting the probability for falls in community-dwelling older adults using the timed up &amp; Go Test. Phys Ther. 2000;80(9):896\u2013903. https:\/\/doi.org\/10.1093\/ptj\/80.9.896.","journal-title":"Phys Ther"},{"issue":"4","key":"2248_CR31","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1519\/JPT.0000000000000068","volume":"39","author":"JT Lang","year":"2016","unstructured":"Lang JT, Kassan TO, Devaney LL, Colon-Semenza C, Joseph MF. Test-retest reliability and minimal detectable change for the 10-meter walk test in older adults with Parkinson's disease. J Geriatr Phys Ther. 2016;39(4):165.","journal-title":"J Geriatr Phys Ther"},{"key":"2248_CR32","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3138\/ptc.48.4.257","volume":"47","author":"K Hill","year":"1996","unstructured":"Hill K, Bernhardt J, McGann A, Maltese D, Berkovits D. A new test of dynamic standing balance for stroke patients: reliability, validity, and quantitative clinical tests. Physiother Can. 1996;47:257\u201362.","journal-title":"Physiother Can"},{"issue":"7","key":"2248_CR33","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1002\/mds.22017","volume":"23","author":"DJ Gill","year":"2008","unstructured":"Gill DJ, Freshman A, Blender JA, Ravina B. The Montreal cognitive assessment as a screening tool for cognitive impairment in Parkinson's disease. Mov Disord. 2008;23(7):1043\u20136. https:\/\/doi.org\/10.1002\/mds.22017.","journal-title":"Mov Disord"},{"issue":"S3","key":"2248_CR34","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/mds.870131315","volume":"13","author":"SL Pullman","year":"1998","unstructured":"Pullman SL. Spiral analysis: a new technique for measuring tremor with a digitizing tablet. Mov Disord. 1998;13(S3):85\u20139.","journal-title":"Mov Disord"},{"issue":"4","key":"2248_CR35","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/NPT.0b013e318235da08","volume":"35","author":"GM Earhart","year":"2011","unstructured":"Earhart GM, Cavanaugh JT, Ellis T, Ford MP, Foreman KB, Dibble L. The 9-hole PEG test of upper extremity function: average values, test-retest reliability, and factors contributing to performance in people with Parkinson disease. J Neurol Phys Ther. 2011;35(4):157\u201363. https:\/\/doi.org\/10.1097\/NPT.0b013e318235da08.","journal-title":"J Neurol Phys Ther"},{"issue":"6","key":"2248_CR36","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1093\/ptj\/78.6.577","volume":"78","author":"F Smithson","year":"1998","unstructured":"Smithson F, Morris ME, Iansek R. Performance on clinical tests of balance in Parkinson's disease. Phys Ther. 1998;78(6):577\u201392. https:\/\/doi.org\/10.1093\/ptj\/78.6.577.","journal-title":"Phys Ther"},{"issue":"5","key":"2248_CR37","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1097\/01.MLR.0000062554.74615.4C","volume":"41","author":"GR Norman","year":"2003","unstructured":"Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41(5):582\u201392. https:\/\/doi.org\/10.1097\/01.MLR.0000062554.74615.4C.","journal-title":"Med Care"},{"issue":"6","key":"2248_CR38","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s40265-019-01098-w","volume":"79","author":"V Cabreira","year":"2019","unstructured":"Cabreira V, Soares-da-Silva P, Massano J. Contemporary options for the management of motor complications in Parkinson\u2019s disease: updated clinical review. Drugs. 2019;79(6):593\u2013608. https:\/\/doi.org\/10.1007\/s40265-019-01098-w.","journal-title":"Drugs."},{"issue":"9","key":"2248_CR39","doi-asserted-by":"publisher","first-page":"404","DOI":"10.5694\/mja17.00993","volume":"208","author":"N Titova","year":"2018","unstructured":"Titova N, Chaudhuri KR. Non-motor Parkinson disease: new concepts and personalised management. Med J Aust. 2018;208(9):404\u20139. https:\/\/doi.org\/10.5694\/mja17.00993.","journal-title":"Med J Aust"},{"issue":"10","key":"2248_CR40","doi-asserted-by":"publisher","first-page":"943","DOI":"10.2174\/1389450115666140826104030","volume":"15","author":"F Lauretani","year":"2014","unstructured":"Lauretani F, Saginario A, Ceda GP, Galuppo L, Ruffini L, Nardelli A, et al. Treatment of the motor and non-motor symptoms in Parkinson\u2019s disease according to cluster symptoms presentation. Curr Drug Targets. 2014;15(10):943\u20137. https:\/\/doi.org\/10.2174\/1389450115666140826104030.","journal-title":"Curr Drug Targets"},{"issue":"2","key":"2248_CR41","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/mds.27602","volume":"34","author":"K Seppi","year":"2019","unstructured":"Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, et al. Update on treatments for nonmotor symptoms of Parkinson's disease\u2014an evidence-based medicine review. Mov Disord. 2019;34(2):180\u201398. https:\/\/doi.org\/10.1002\/mds.27602.","journal-title":"Mov Disord"},{"issue":"10","key":"2248_CR42","first-page":"e3474","volume":"10","author":"S Bratsos","year":"2018","unstructured":"Bratsos S, Karponis D, Saleh SN. Efficacy and safety of deep brain stimulation in the treatment of parkinson\u2019s disease: a systematic review and meta-analysis of randomized controlled trials. Cureus. 2018;10(10):e3474.","journal-title":"Cureus"},{"issue":"9","key":"2248_CR43","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1002\/mds.27779","volume":"34","author":"S Moosa","year":"2019","unstructured":"Moosa S, Mart\u00ednez-Fern\u00e1ndez R, Elias WJ, Del Alamo M, Eisenberg HM, Fishman PS. The role of high-intensity focused ultrasound as a symptomatic treatment for Parkinson's disease. Mov Disord. 2019;34(9):1243\u201351. https:\/\/doi.org\/10.1002\/mds.27779.","journal-title":"Mov Disord"},{"issue":"7","key":"2248_CR44","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1080\/13543784.2020.1771693","volume":"29","author":"A Antonini","year":"2020","unstructured":"Antonini A, Bravi D, Sandre M, Bubacco L. Immunization therapies for Parkinson\u2019s disease: state of the art and considerations for future clinical trials. Expert Opin Investig Drugs. 2020;29(7):685\u201395. https:\/\/doi.org\/10.1080\/13543784.2020.1771693.","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"2248_CR45","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41583-019-0257-7","volume":"21","author":"M Parmar","year":"2020","unstructured":"Parmar M, Grealish S, Henchcliffe C. The future of stem cell therapies for Parkinson disease. Nat Rev Neurosci. 2020;21(2):103\u201315. https:\/\/doi.org\/10.1038\/s41583-019-0257-7.","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"2248_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.parkreldis.2010.08.012","volume":"17","author":"S-E Soh","year":"2011","unstructured":"Soh S-E, Morris ME, McGinley JL. Determinants of health-related quality of life in Parkinson\u2019s disease: a systematic review. Parkinsonism Relat Disord. 2011;17(1):1\u20139. https:\/\/doi.org\/10.1016\/j.parkreldis.2010.08.012.","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"2248_CR47","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1093\/ptj\/81.2.810","volume":"81","author":"S Morris","year":"2001","unstructured":"Morris S, Morris ME, Iansek R. Reliability of measurements obtained with the timed \u201cup & go\u201d test in people with Parkinson disease. Phys Ther. 2001;81(2):810\u20138. https:\/\/doi.org\/10.1093\/ptj\/81.2.810.","journal-title":"Phys Ther"},{"issue":"12","key":"2248_CR48","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.1589\/jpts.27.3675","volume":"27","author":"N Paker","year":"2015","unstructured":"Paker N, Bugdayci D, Goksenoglu G, Demircio\u011flu DT, Kesiktas N, Ince N. Gait speed and related factors in Parkinson\u2019s disease. J Phys Ther Sci. 2015;27(12):3675\u20139. https:\/\/doi.org\/10.1589\/jpts.27.3675.","journal-title":"J Phys Ther Sci"},{"issue":"11","key":"2248_CR49","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1007\/s004150170047","volume":"248","author":"BR Bloem","year":"2001","unstructured":"Bloem BR, Grimbergen YAM, Cramer M, Willemsen M, Zwinderman AH. Prospective assessment of falls in Parkinson's disease. J Neurol. 2001;248(11):950\u20138. https:\/\/doi.org\/10.1007\/s004150170047.","journal-title":"J Neurol"},{"key":"2248_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12938-020-00776-1","volume":"19","author":"Z Rahmati","year":"2020","unstructured":"Rahmati Z, Behzadipour S, Schouten AC, Taghizadeh G, Firoozbakhsh K. Postural control learning dynamics in Parkinson\u2019s disease: early improvement with plateau in stability, and continuous progression in flexibility and mobility. Biomed Eng Online. 2020;19:1\u201322.","journal-title":"Biomed Eng Online"},{"issue":"4","key":"2248_CR51","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1590\/s1980-5764-2016dn1004005","volume":"10","author":"AF Barbosa","year":"2016","unstructured":"Barbosa AF, Chen J, Freitag F, Valente D, Souza CO, Voos MC, et al. gait, posture and cognition in Parkinson's disease. Dement Neuropsychol. 2016;10(4):280\u20136. https:\/\/doi.org\/10.1590\/s1980-5764-2016dn1004005.","journal-title":"Dement Neuropsychol"},{"key":"2248_CR52","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2147\/IJGM.S65803","volume":"7","author":"G Christofoletti","year":"2014","unstructured":"Christofoletti G, Andrade LP, Beinotti F, Borges G. Cognition and dual-task performance in older adults with Parkinson\u2019s and Alzheimer\u2019s disease. Int J Gen Med. 2014;7:383.","journal-title":"Int J Gen Med"},{"issue":"3","key":"2248_CR53","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/j.1750-3639.2009.00369.x","volume":"20","author":"D Aarsland","year":"2010","unstructured":"Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson's disease. Brain Pathol. 2010;20(3):633\u20139. https:\/\/doi.org\/10.1111\/j.1750-3639.2009.00369.x.","journal-title":"Brain Pathol"},{"issue":"7","key":"2248_CR54","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1093\/arclin\/acaa039","volume":"35","author":"AF Mazancova","year":"2020","unstructured":"Mazancova AF, R\u016f\u017ei\u010dka E, Jech R, Bezdicek O. Test the best: classification accuracies of four cognitive rating scales for Parkinson\u2019s disease mild cognitive impairment. Arch Clin Neuropsychol. 2020;35(7):1069\u201377. https:\/\/doi.org\/10.1093\/arclin\/acaa039.","journal-title":"Arch Clin Neuropsychol"},{"issue":"11","key":"2248_CR55","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1089\/neu.2013.3244","volume":"31","author":"MA Naeser","year":"2014","unstructured":"Naeser MA, Zafonte R, Krengel MH, Martin PI, Frazier J, Hamblin MR, et al. Significant improvements in cognitive performance post-transcranial, red\/near-infrared light-emitting diode treatments in chronic, mild traumatic brain injury: open-protocol study. J Neurotrauma. 2014;31(11):1008\u201317. https:\/\/doi.org\/10.1089\/neu.2013.3244.","journal-title":"J Neurotrauma"},{"issue":"2","key":"2248_CR56","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/gps.5039","volume":"34","author":"AS Chan","year":"2019","unstructured":"Chan AS, Lee TL, Yeung MK, Hamblin MR. Photobiomodulation improves the frontal cognitive function of older adults. Int J Geriatr Psychiatry. 2019;34(2):369\u201377. https:\/\/doi.org\/10.1002\/gps.5039.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"1","key":"2248_CR57","doi-asserted-by":"publisher","first-page":"176","DOI":"10.21767\/2171-6625.1000176","volume":"8","author":"MH Berman","year":"2017","unstructured":"Berman MH, Halper JP, Nichols TW, Jarrett H, Lundy A, Huang JH. Photobiomodulation with near infrared light helmet in a pilot, placebo controlled clinical trial in dementia patients testing memory and cognition. J Neurol Neurosci. 2017;8(1):176.","journal-title":"J Neurol Neurosci"},{"issue":"3","key":"2248_CR58","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1089\/photob.2018.4569","volume":"37","author":"F Salehpour","year":"2019","unstructured":"Salehpour F, Hamblin MR, DiDuro JO. Rapid reversal of cognitive decline, olfactory dysfunction, and quality of life using multi-modality photobiomodulation therapy: case report. Photobiomodul Photomed Laser Surg. 2019;37(3):159\u201367. https:\/\/doi.org\/10.1089\/photob.2018.4569.","journal-title":"Photobiomodul Photomed Laser Surg"},{"issue":"8","key":"2248_CR59","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1089\/pho.2016.4227","volume":"35","author":"AE Saltmarche","year":"2017","unstructured":"Saltmarche AE, Naeser MA, Ho KF, Hamblin MR, Lim L. Significant improvement in cognition in mild to moderately severe dementia cases treated with transcranial plus intranasal photobiomodulation: case series report. Photomed Laser Surg. 2017;35(8):432\u201341. https:\/\/doi.org\/10.1089\/pho.2016.4227.","journal-title":"Photomed Laser Surg"},{"key":"2248_CR60","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jocn.2018.10.043","volume":"61","author":"C Brooks","year":"2019","unstructured":"Brooks C, Eden G, Chang A, Demanuele C, Kelley Erb M, Shaafi Kabiri N, et al. Quantification of discrete behavioral components of the MDS-UPDRS. J Clin Neurosci. 2019;61:174\u20139. https:\/\/doi.org\/10.1016\/j.jocn.2018.10.043.","journal-title":"J Clin Neurosci"},{"issue":"8","key":"2248_CR61","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1007\/s00415-019-09348-3","volume":"266","author":"A Regnault","year":"2019","unstructured":"Regnault A, Boroojerdi B, Meunier J, Bani M, Morel T, Cano S. Does the MDS-UPDRS provide the precision to assess progression in early Parkinson's disease? Learnings from the Parkinson's progression marker initiative cohort. J Neurol. 2019;266(8):1927\u201336. https:\/\/doi.org\/10.1007\/s00415-019-09348-3.","journal-title":"J Neurol"},{"issue":"10","key":"2248_CR62","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1002\/mds.27790","volume":"34","author":"LJ Evers","year":"2019","unstructured":"Evers LJ, Krijthe JH, Meinders MJ, Bloem BR, Heskes TM. Measuring Parkinson's disease over time: the real-world within-subject reliability of the MDS-UPDRS. Mov Disord. 2019;34(10):1480\u20137. https:\/\/doi.org\/10.1002\/mds.27790.","journal-title":"Mov Disord"},{"issue":"2","key":"2248_CR63","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/ptj\/85.2.134","volume":"85","author":"K Brusse","year":"2005","unstructured":"Brusse K, Zimdars S, Zalewski K, Steffen T. Testing functional performance in people with Parkinson disease. Phys Ther. 2005;85(2):134\u201341. https:\/\/doi.org\/10.1093\/ptj\/85.2.134.","journal-title":"Phys Ther"},{"issue":"5","key":"2248_CR64","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1179\/016164107X251772","volume":"30","author":"S Holroyd","year":"2008","unstructured":"Holroyd S, Currie LJ, Wooten GF. Validity, sensitivity and specificity of the mentation, behavior and mood subscale of the UPDRS. Neurol Res. 2008;30(5):493\u20136. https:\/\/doi.org\/10.1179\/016164107X251772.","journal-title":"Neurol Res"},{"issue":"4","key":"2248_CR65","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.jbmt.2019.02.009","volume":"23","author":"M Fleischmann","year":"2019","unstructured":"Fleischmann M, Vaughan B. Commentary: statistical significance and clinical significance - a call to consider patient reported outcome measures, effect size, confidence interval and minimal clinically important difference (MCID). J Bodyw Mov Ther. 2019;23(4):690\u20134. https:\/\/doi.org\/10.1016\/j.jbmt.2019.02.009.","journal-title":"J Bodyw Mov Ther"},{"issue":"4","key":"2248_CR66","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","volume":"10","author":"R Jaeschke","year":"1989","unstructured":"Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10(4):407\u201315. https:\/\/doi.org\/10.1016\/0197-2456(89)90005-6.","journal-title":"Control Clin Trials"},{"issue":"5","key":"2248_CR67","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1097\/01.MLR.0000064706.35861.B4","volume":"41","author":"DE Beaton","year":"2003","unstructured":"Beaton DE. Simple as possible? Or too simple?: possible limits to the universality of the one half standard deviation. Med Care. 2003;41(5):593\u20136. https:\/\/doi.org\/10.1097\/01.MLR.0000064706.35861.B4.","journal-title":"Med Care"},{"issue":"10","key":"2248_CR68","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1089\/pho.2018.4527","volume":"36","author":"A Liebert","year":"2018","unstructured":"Liebert A. Emerging applications of photobiomodulation therapy: the interaction between metabolomics and the microbiome. Photomed Laser Surg. 2018;36(10):515\u20137. https:\/\/doi.org\/10.1089\/pho.2018.4527.","journal-title":"Photomed Laser Surg"},{"issue":"1\u20132","key":"2248_CR69","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.pain.2006.05.018","volume":"124","author":"RT Chow","year":"2006","unstructured":"Chow RT, Heller GZ, Barnsley L. The effect of 300 mW, 830 nm laser on chronic neck pain: a double-blind, randomized, placebo-controlled study. Pain. 2006;124(1\u20132):201\u201310. https:\/\/doi.org\/10.1016\/j.pain.2006.05.018.","journal-title":"Pain."},{"issue":"3","key":"2248_CR70","doi-asserted-by":"publisher","first-page":"e000628","DOI":"10.1136\/bmjopen-2011-000628","volume":"2","author":"AW Shukla","year":"2012","unstructured":"Shukla AW, Ounpraseuth S, Okun MS, Gray V, Schwankhaus J, Metzer WS. Micrographia and related deficits in Parkinson's disease: a cross-sectional study. BMJ Open. 2012;2(3):e000628.","journal-title":"BMJ Open"},{"issue":"4","key":"2248_CR71","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.humov.2010.08.008","volume":"30","author":"C Bidet-Ildei","year":"2011","unstructured":"Bidet-Ildei C, Pollak P, Kandel S, Fraix V, Orliaguet J. Handwriting in patients with Parkinson disease: effect of l-dopa and stimulation of the sub-thalamic nucleus on motor anticipation. Hum Mov Sci. 2011;30(4):783\u201391. https:\/\/doi.org\/10.1016\/j.humov.2010.08.008.","journal-title":"Hum Mov Sci"},{"issue":"6","key":"2248_CR72","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/S0166-2236(02)02181-1","volume":"25","author":"R de la Fuente-Fern\u00e1ndez","year":"2002","unstructured":"de la Fuente-Fern\u00e1ndez R, Stoessl AJ. The placebo effect in Parkinson's disease. Trends Neurosci. 2002;25(6):302\u20136. https:\/\/doi.org\/10.1016\/S0166-2236(02)02181-1.","journal-title":"Trends Neurosci"},{"issue":"3","key":"2248_CR73","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jclinepi.2013.08.015","volume":"67","author":"J McCambridge","year":"2014","unstructured":"McCambridge J, Witton J, Elbourne DR. Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects. J Clin Epidemiol. 2014;67(3):267\u201377. https:\/\/doi.org\/10.1016\/j.jclinepi.2013.08.015.","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"2248_CR74","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/S1474-4422(16)00066-1","volume":"15","author":"F Benedetti","year":"2016","unstructured":"Benedetti F, Carlino E, Piedimonte A. Increasing uncertainty in CNS clinical trials: the role of placebo, nocebo, and Hawthorne effects. Lancet Neurol. 2016;15(7):736\u201347. https:\/\/doi.org\/10.1016\/S1474-4422(16)00066-1.","journal-title":"Lancet Neurol"},{"issue":"6","key":"2248_CR75","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1080\/08039488.2018.1468480","volume":"72","author":"BM Morberg","year":"2018","unstructured":"Morberg BM, Malling AS, Jensen BR, Gredal O, Wermuth L, Bech P. The Hawthorne effect as a pre-placebo expectation in Parkinsons disease patients participating in a randomized placebo-controlled clinical study. Nordic J Psychiatry. 2018;72(6):442\u20136. https:\/\/doi.org\/10.1080\/08039488.2018.1468480.","journal-title":"Nordic J Psychiatry"},{"issue":"3","key":"2248_CR76","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1123\/jab.2013-0319","volume":"31","author":"V Robles-Garc\u00eda","year":"2015","unstructured":"Robles-Garc\u00eda V, Corral-Berganti\u00f1os Y, Espinosa N, J\u00e1come MA, Garc\u00eda-Sancho C, Cudeiro J, et al. Spatiotemporal gait patterns during overt and covert evaluation in patients with Parkinson\u2019s disease and healthy subjects: is there a Hawthorne effect? J Appl Biomech. 2015;31(3):189\u201394. https:\/\/doi.org\/10.1123\/jab.2013-0319.","journal-title":"J Appl Biomech"},{"issue":"2","key":"2248_CR77","first-page":"21","volume":"96","author":"WJ Choi","year":"2019","unstructured":"Choi WJ, Jung JJ, Grantcharov TP. Impact of Hawthorne effect on healthcare professionals: a systematic review. Univ Tor Med J. 2019;96(2):21\u201332.","journal-title":"Univ Tor Med J"},{"key":"2248_CR78","first-page":"987621","volume":"2013","author":"KB Foreman","year":"2013","unstructured":"Foreman KB, Sondrup S, Dromey C, Jarvis E, Nissen S, Dibble LE. The effects of practice on the concurrent performance of a speech and postural task in persons with Parkinson disease and healthy controls. Parkinson\u2019s Dis. 2013;2013:987621.","journal-title":"Parkinson\u2019s Dis"},{"issue":"6","key":"2248_CR79","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1007\/s10103-019-02898-y","volume":"35","author":"HL Casalechi","year":"2020","unstructured":"Casalechi HL, Dumont AJL, Ferreira LAB, de Paiva PRV, Machado CSM, de Carvalho PTC, et al. Acute effects of photobiomodulation therapy and magnetic field on functional mobility in stroke survivors: a randomized, sham-controlled, triple-blind, crossover, clinical trial. Lasers Med Sci. 2020;35(6):1253\u201362. https:\/\/doi.org\/10.1007\/s10103-019-02898-y.","journal-title":"Lasers Med Sci"},{"key":"2248_CR80","doi-asserted-by":"publisher","unstructured":"Lamartiniere R, Bergeron R, Aung-Din R, Bennett M, Stephan W, Banas L. Chapter 42 - Photobiomodulation treatment for brain disorders: posttraumatic stress disorder (PTSD) and dementia. In: Hamblin MR, Huang Y-Y, editors. Photobiomodulation in the Brain: Academic Press; 2019. p. 589\u201397. https:\/\/doi.org\/10.1016\/B978-0-12-815305-5.00042-7.","DOI":"10.1016\/B978-0-12-815305-5.00042-7"},{"key":"2248_CR81","volume-title":"Psychological benefits 2 and 4 weeks after a single treatment with near infrared light to the forehead: a pilot study of 10 patients with major depression and anxiety","author":"AL Johnston","year":"2009","unstructured":"Johnston AL, Schiffer F, Ravichandran CT, Polcari A, Teicher MH, Webb RH, et al. Psychological benefits 2 and 4 weeks after a single treatment with near infrared light to the forehead: a pilot study of 10 patients with major depression and anxiety. 2009."},{"issue":"1","key":"2248_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-42693-x","volume":"9","author":"R Zomorrodi","year":"2019","unstructured":"Zomorrodi R, Loheswaran G, Pushparaj A, Lim L. Pulsed near infrared transcranial and intranasal photobiomodulation significantly modulates neural oscillations: a pilot exploratory study. Sci Rep. 2019;9(1):1\u201311.","journal-title":"Sci Rep"},{"key":"2248_CR83","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.neuroscience.2019.10.037","volume":"422","author":"H El Khoury","year":"2019","unstructured":"El Khoury H, Mitrofanis J, Henderson LA. Exploring the effects of near infrared light on resting and evoked brain activity in humans using magnetic resonance imaging. Neuroscience. 2019;422:161\u201371. https:\/\/doi.org\/10.1016\/j.neuroscience.2019.10.037.","journal-title":"Neuroscience."},{"key":"2248_CR84","doi-asserted-by":"publisher","unstructured":"Hamilton C, Hamilton D, Nicklason F, Mitrofanis J. Transcranial photobiomodulation therapy: observations from four movement disorder patients. In: Caldieraro M, Cassano P, editors. Photobiomodulation in the Brain: Elsevier; 2019. p. 463\u201372. https:\/\/doi.org\/10.1016\/B978-0-12-815305-5.00033-6.","DOI":"10.1016\/B978-0-12-815305-5.00033-6"},{"issue":"3","key":"2248_CR85","doi-asserted-by":"publisher","first-page":"031404","DOI":"10.1117\/1.NPh.3.3.031404","volume":"3","author":"P Cassano","year":"2016","unstructured":"Cassano P, Petrie S, Hamblin M, Henderson T, Iosifescu D. Review of transcranial photobiomodulation for major depressive disorder: targeting brain metabolism, inflammation, oxidative stress, and neurogenesis. Neurophotonics. 2016;3(3):031404. https:\/\/doi.org\/10.1117\/1.NPh.3.3.031404.","journal-title":"Neurophotonics."},{"issue":"2","key":"2248_CR86","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s10103-013-1356-8","volume":"29","author":"AAM Lima","year":"2014","unstructured":"Lima AAM, Sp\u00ednola LG, Baccan G, Correia K, Oliva M, Vasconcelos JF, et al. Evaluation of corticosterone and IL-1\u03b2, IL-6, IL-10 and TNF-\u03b1 expression after 670-nm laser photobiomodulation in rats. Lasers Med Sci. 2014;29(2):709\u201315. https:\/\/doi.org\/10.1007\/s10103-013-1356-8.","journal-title":"Lasers Med Sci"},{"issue":"3","key":"2248_CR87","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1096\/fj.201901917RR","volume":"34","author":"Z Al Amir Dache","year":"2020","unstructured":"Al Amir Dache Z, Otandault A, Tanos R, Pastor B, Meddeb R, Sanchez C, et al. Blood contains circulating cell-free respiratory competent mitochondria. FASEB J. 2020;34(3):3616\u201330. https:\/\/doi.org\/10.1096\/fj.201901917RR.","journal-title":"FASEB J"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-021-02248-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-021-02248-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-021-02248-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:02:58Z","timestamp":1625184178000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-021-02248-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,2]]},"references-count":87,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2248"],"URL":"https:\/\/doi.org\/10.1186\/s12883-021-02248-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.05.26.21257833","asserted-by":"object"}]},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,2]]},"assertion":[{"value":"28 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study received human research ethics approval by the Griffith University Human Research Ethics Committee (2018\/16). All participants gave written informed consent prior to taking part in the study. All protocols were approved by the Griffith University Human Research Ethics Committee and were conducted in accordance with their regulations and guidelines.Consent for publication.Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"AL and BB, since February 2020, are co-founders, directors and current employees of SYMBYX Pty Ltd., a med-tech company developing treatments for neurological disorders. BB is an agent for Spectro Analytic Irradia AB, a laser manufacturer. The other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"256"}}